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ABSTRACT 
While nicotine replacement therapy (NRT) is presumed to be a safer alternative to smoking 
in pregnancy, the long-term consequences in offspring are still largely unknown. Animal 
studies now suggest that maternal nicotine exposure during pregnancy and lactation (MNE-
PL) leads to a wide variety of adverse outcomes for the offspring, including increased 
adiposity. The focus of this study was to investigate how MNE-PL in rats may lead to liver 
dysfunction long-term in offspring through alterations in gene expression and epigenetic 
modifications. Postnatal day 180 (PND180) offspring exposed to nicotine during pregnancy 
and lactation (1mg/kg/day) exhibited increased circulating and hepatic triglycerides 
concomitant with increased expression of fatty acid synthase (FAS), an enzyme involved in 
hepatic de novo fatty acid synthesis. Furthermore, we demonstrate that MNE-PL offspring 
displayed increased protein expression of the Liver X Receptor α (LXRα), a key regulator of 
FAS. Chromatin immunoprecipitation revealed enriched binding of LXRα to the putative 
LXRE element on the FAS promoter in PND180 male offspring. This was associated with 
enhanced acetylation of histone H3 [K9,14] surrounding the FAS promoter, a hallmark of 
chromatin activation. Collectively, these findings suggest that nicotine exposure during 
pregnancy and lactation leads to increased circulating and hepatic triglyceride levels long-
term via changes in transcriptional and epigenetic regulation of the hepatic lipogenic 
pathway. 
 
Keywords: Nicotine Replacement Therapy (NRT), Triglycerides, Fatty Acid Synthase 
(FAS), Liver, Liver X Receptor (LXR), Obesity, Fetal Programming  
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CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Nicotine  
1.1.1 Maternal smoking and obesity  
 Despite the well-established links between smoking during pregnancy and 
increased risk of placental complications (1), impaired fetal growth (2, 3) and perinatal 
mortality (2, 3), approximately 10-20% of Canadian mothers continue to smoke during 
pregnancy (4, 5). This translates to approximately ~75,000 babies born each year in 
Canada alone who were exposed to first hand smoke in utero (2, 5). Unfortunately, the 
global prevalence of tobacco smoking in young mothers continues to rise in low- and 
middle-income countries (6). In addition, over half of the women who are able to quit 
smoking during pregnancy will relapse within four months of delivery (7). If women 
cannot abstain from smoking during pregnancy, a recent meta-analysis of thirty 
prospective studies now suggests that their children have a 47% increase in the odds of 
becoming overweight (8). Since smoking during pregnancy is a highly modifiable risk 
factor, women are willingly predisposing their children to obesity at birth (9). It is 
noteworthy to mention that some studies have identified a higher risk of children being 
overweight if their mother was overweight prepregnancy (10). However, the association 
between smoking and childhood obesity was found to be unaffected by maternal diet, 
parental body size or gestational weight gain(11, 12). Therefore pathways independent of 
a mother’s lifestyle may be playing a role in the long-term health and disease risk in 
children. Numerous clinical studies have now found that adults exposed to smoking in 
utero have increased plasma triglycerides, a characteristic often associated with obesity 
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and the metabolic syndrome (13-16). This is of great concern considering that elevated 
plasma triglycerides levels are an independent risk factor that is significantly associated 
with cardiovascular (CV) disease (17, 18). Given that nearly one-third of Canadian 
children and youth (5- to 17- years old) are either overweight or obese (19), and the risk 
that elevated triglycerides pose (17, 18), it is clear that these situations warrant strategies 
for the prevention or reduction of hypertriglyceridemia.  
1.1.2 Nicotine replacement therapy (NRT) 
 Although cigarette smoking is one of the most important and modifiable risk 
factors leading to adverse obstetrical outcomes (2, 9), nicotine dependence still remains 
the driving force behind continued smoking behaviour (20-22). Consequently, nicotine 
replacement therapy (NRT) has been widely developed as an effective therapy for 
smoking cessation (20, 22). NRT provides a substitute source of nicotine that 
significantly reduces the symptoms of cigarette withdrawal including irritability, hunger 
and sleepiness (23, 24). NRT exists in various forms including gums, transdermal 
patches, nasal sprays, inhalers and lozenges that differ in route of administration and dose 
of nicotine (25). All NRT formulations are considered more effective as either the main 
or supportive therapy used, compared to placebo or no treatment in smoking cessation 
(26). The efficacy of NRT is largely based on the individual and will differ between 
people based on factors such as the setting in which NRT is administered, source of 
motivation for quitting and a smoker’s level of dependency on nicotine (27). A 
systematic review of studies evaluating the commercially available forms of NRT found 
that NRT alone increases the odds of smoking cessation 1.5 to 2-fold independent of 
additional support and setting (28, 29).  
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 It is important to give special consideration to pregnant women using NRT 
because of the harm nicotine exposure may pose for the developing fetus. Although NRT 
appears to be a safer alternative to smoking in pregnancy as the number of chemicals is 
reduced from 4000 to 1, there is little evidence validating this claim (30, 31). To date, 
there is insufficient data available on the effectiveness of NRT during pregnancy or on 
the potential risks it may pose (32). Despite this oversight, obstetricians continue to 
prescribe NRT in pregnancy, highlighting the urgent need to study both safety and 
efficacy of NRT in this population (33, 34). Moreover, understanding the long-term 
consequences of maternal nicotine exposure (MNE) in offspring can provide insight into 
determining a safe dose and management of NRT use in pregnancy.   
 In addition to the numerous health benefits of abstaining from smoking in 
pregnancy, prenatal smoking cessation therapies provide additional economic benefits. 
For instance, approximately every dollar invested in smoking cessation therapies can 
result in up to three dollars saved in costs from the prevention of neonatal complications 
and neonatal intensive care unit expenses (35).   
1.1.3 Pharmacology of nicotine  
 Nicotine (C10H14N2) is a weak base and a relatively lipophilic compound, which 
facilitates its ability to cross cell membranes in its unionized form (36-38). Accordingly, 
various forms of NRT are buffered in an alkaline pH for absorption by the body (36). In 
contrast to nicotine absorption from cigarette smoke, NRT results in a gradual absorption 
of nicotine and reduces the likelihood of abuse by users (36, 39). Nicotine is absorbed 
with high affinity in the brain, muscle, liver, lung, spleen and kidney (40, 41). Due to the 
biological nature of nicotine, it is able to cross the placenta and mammary glands leading 
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to the accumulation of nicotine in fetal serum and breast milk, respectively (42-45). 
Studies have demonstrated that human fetuses are exposed to higher levels of nicotine in 
the placenta, amniotic fluid and serum compared to levels measured in the maternal 
serum (46).  
1.1.4 Pharmacokinetics of nicotine  
 Nicotine is primarily metabolized in the liver and to a small degree in the lung 
and brain (36, 47-49). Phase I metabolism of nicotine is mainly via the C-oxidation 
pathway, which converts nicotine to cotinine. The C-oxidation pathway accounts for 
approximately 72% of total nicotine metabolism (50). C-oxidation begins with the 
conversion of nicotine to a nicotine ∆1’(5') iminium ion catalyzed by the liver cytochrome 
P450 2A6 (CYP 2A6) enzyme (51-53). Genetic variations of this gene are postulated to 
be the cause of inter-individual variability in nicotine metabolism (54). The nicotine ∆1’ 
(5') iminium ion is converted by an aldehyde oxidase, the main enzyme involved in the 
final step of the metabolism to cotinine (52, 55-57). Cotinine may be further metabolized 
into a variety of metabolites, including the largest single metabolite 3’-trans-
hydroxycotinine via CYP 2A6 (53). Nicotine and its metabolites undergo phase II 
metabolism through a variety of glucoronidation reactions that convert the parent 
substrates into more water-soluble compounds for excretion (36, 58-60). Finally, nicotine 
and its metabolites are eliminated predominantly through renal excretion and to a small 
degree in sweat and breast milk (61-64).  
 It is important to consider the changes in nicotine and cotinine clearance rates that 
occur during pregnancy. In pregnancy, nicotine metabolism increases by approximately 
50%, while nicotine absorption does not differ between pregnancy and postpartum (41, 
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65).  Correspondingly, cotinine metabolism increases by 140% (65). The elevations to 
nicotine and cotinine metabolism in pregnant women are postulated to be a result of 
increased hepatic metabolism by CYP 2A6 concomitant with faster levels of 
glucuronidation (65). Although an increase in blood flow to the liver could explain an 
increase in nicotine metabolism, nearly no difference is found in blood flow to the liver 
during pregnancy (65). Therefore, increased clearance rates are likely due to an induction 
of drug metabolizing enzymes in the liver during pregnancy (65, 66). Further 
investigation is warranted to determine if the effective dosage of NRT should be 
increased in order to accommodate the physiological changes in pregnancy (65).  
1.1.5 Action of nicotine  
 Nicotine is a tertiary amine that binds to nicotinic acetylcholine receptors 
(nAChRs) found mainly in the brain, autonomic ganglia and at neuromuscular junctions 
(67). Upon binding, nAChRs undergo allosteric changes that increase their permeability 
to calcium ions and trigger the release of neurotransmitters such as acetylcholine, 
norephinephrine, dopamine, and serotonin (68). Specifically, the binding of nicotine to 
the α4β2 nAChR likely mediates nicotine dependency (69). The addictive nature of 
nicotine has been linked to the subsequent release of dopamine that leads to pleasurable 
experiences, mood modulation and stimulation (69). Nicotine addiction develops due to 
its positive reinforcing effects while avoiding withdrawal symptoms such as anxiety and 
stress (68).  
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1.2 Lipogenesis  
1.2.1 Overview of the development and functions of the liver 
 Liver development begins in endodermal cells in the ventral foregut that are 
specified for a hepatic fate. Through the coordination of a network of transcription 
factors, these cells express new genes such as albumin and α-fetoprotein that commit 
cells to develop into hepatoblasts. Hepatoblasts in the liver will bud and eventually 
differentiate into hepatocytes or bile duct cells. Hepatocytes, the primary cells of the 
liver, undergo extensive morphology and maturational changes before and after birth in 
both rodents and humans (70, 71).  
 The cells within the liver are highly organized in order to carry out a myriad of 
functions. In brief, blood enters the liver through the hepatic artery and leaves through the 
hepatic vein. Blood travels through the liver via sinusoids, which consist of small 
capillaries, lined with highly fenestrated endothelial cells to allow for the exchange 
between the bloodstream and hepatocytes. The structure of the liver allows for the 
compartmentalization of function depending on the location of hepatocytes. As a result, 
hepatocytes are able to carry out various metabolic pathways in distinct regions of the 
liver (71).  
 The liver possesses several vital functions in the body including the production of 
bile, detoxification of xenobiotic agents, breakdown of toxic endogenous compounds, 
maintenance of cholesterol homeostasis, regulation of gluconeogenesis and the synthesis 
and metabolism of lipids (71). 
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1.2.2 The role of the liver and adipose tissue in lipogenesis  
 Lipogenesis is the synthesis of fatty acids and the subsequent formation of 
triglycerides, which mainly occurs in the liver and adipose tissue (72). Fatty acids can 
become oxidized or undergo esterification reactions to form triglycerides (73).  The liver 
maintains lipid homeostasis in part through a balance between lipid storage and lipid 
metabolism. The liver obtains free fatty acids from either lipolysis of adipose tissue or 
through de novo fatty acid synthesis (73). Interestingly, it has been shown that both de 
novo lipogenesis and reesterification of peripheral fatty acids contribute to the elevated 
levels of triglycerides observed in patients with abnormal lipid accumulation in the liver 
(74).   
 In addition to the liver, adipose tissue also plays a fundamental role in 
lipogenesis. Adipose tissue constitutes a large energy reservoir in the body that stores 
energy in the form of triglycerides that are absorbed from the circulation (75, 76). Almost 
90% of adipocyte cell volume is made up of lipid droplets consisting of fats, 
triglycerides, fatty acids, phospholipids and cholesterol (75). In response to lipid 
requirements by other tissues, triglycerides in adipose tissue are hydrolyzed and released 
into the bloodstream as free fatty acids and glycerol molecules (77). Although adipose 
tissue can undergo de novo lipogenesis, studies have shown that it does not greatly 
contribute to the maintenance of excess fat in obese patients (78). In contrast, enhanced 
hepatic lipogenesis has been found to contribute to increased triglyceride pools and 
maintenance of excess fat in obese patients (78).   
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1.2.3 Hepatic de novo lipogenesis  
 Lipid synthesis in the liver begins with the uptake of glucose through the glucose 
transporter 2 (Glut2) (79).  Once glycogen stores have been maximized, excess glucose is 
converted into triglycerides (80). Glucose enters the glycolytic pathway to form pyruvate, 
which then undergoes decarboxylation reactions by pyruvate dehydrogenase to form 
acetyl-CoA(81-84). Acetyl-CoA carboxylase (ACCα), a cytoplasmic enzyme, converts 
acetyl-CoA to malonyl-CoA, a committed step in fatty acid synthesis (85). Malonyl-CoA 
is essential for the production of long chain fatty acids such as palmitate and is a substrate 
for the fatty acid synthase (FAS) enzyme (85, 86). FAS catalyzes the conversion of 
palmitate to its major product palmitic acid through successive additions of malonyl-CoA 
to an acetyl-CoA molecule (87). Subsequently, stearoyl-CoA desaturase-1 (SCD-1) 
located in the endoplasmic reticulum (ER) converts palmitoyl- and stearoyl-CoA into 
monounsaturated fatty acids (MUFAs), palmitoleate and oleate, respectively (88). 
MUFAs undergo further desaturation and elongation reactions before becoming 
incorporated into various lipid products including triglycerides (Fig 1.2.3) (88).   
 Gene knockdown studies in mice have been used to elucidate the source of 
MUFAs used in triglyceride incorporation. Mice lacking SCD-1 were found to have 
approximately 60% lower liver and circulating triglyceride levels compared to 
heterogeneous mice (89). Notably, an exogenous source of MUFAs was unable to rescue 
the abnormal triglyceride profile in deficient mice, suggesting that endogenously 
synthesized MUFAs are the main substrate for hepatic de novo triglyceride synthesis 
(89). Given that endogenous MUFAs are formed in the ER, they are in close proximity to 
the enzymes involved in triglyceride synthesis. Therefore, endogenous MUFAs are more 
 readily available at the site of triglyceride synthesis compared to MUFAs derived from 
dietary sources (89, 90).  
 Triglycerides consist of a glycerol moiety with fatty acids e
hydroxyls (91). While studies have implicated enhanced 
with augmented plasma triglycerides, the role of
enzymes in nicotine-induced hypertriglyceridemia is currently unknown
 
 
 
 
 
 
 
Fig.  1.2.3 Overview of the hepatic 
The synthesis of fatty acids requires key enzymes including acetyl Co
carboxylase (ACCα) and fatty acid synthase (FAS).  Stearoyl
(SCD-1) is required for the desaturation of fatty acids, while elongase (Elovl) 
enzymes, glycerol-
acyltransferase (DGAT
sterified to all three 
hepatic lipogenesis in patients 
 the individual fatty acid biosynthetic
 
de novo triglyceride synthesis pathway.
-CoA desaturase 1 
3-phosphate acyltransferase (GPAT) and d
) are required for triglyceride synthesis.  
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1.2.4 The regulation of lipogenic genes   
 Nutritional status and hormones are well known regulators of lipogenesis. Studies 
examining the effect of nutrition supplementation in rats, have found that fasted animals 
have significantly lower FAS enzymatic activity in the liver compared to fed animals (92, 
93). Moreover, refeeding was shown to lead to an increase in absolute protein content of 
hepatic FAS by 30- to 50-fold in rats (93). Two major mechanisms have been considered 
linking nutritional status and the transcriptional regulation of lipogenesis. Firstly being 
that glucose itself is a substrate for lipogenesis, and secondly that glucose stimulates the 
release of insulin (72, 94).  
 Insulin has been identified as an important regulator of lipogenesis. 
Streptozotocin (STZ)-induced diabetic mice show that treatment with insulin resulted in a 
rapid restoration of FAS enzymatic activity and mRNA levels. Although the rates of FAS 
activity decreased over time, the induction of steady-state mRNA was maintained three 
days after insulin administration, demonstrating that insulin primarily stimulates the 
transcription of the FAS gene (92).  Insulin is able to exert its regulatory effect through 
the action of the transcription factor, sterol regulatory element-binding protein -1c 
(SREBP-1c). Studies in primary cultured rodent hepatocytes found that in the absence of 
insulin, SREBP-1c was not expressed. However, the addition of insulin led to an 
induction of SREBP-1c protein expression (95, 96).  Furthermore, in vivo studies have 
demonstrated that SREBP-1c deficient mice, exposed to either fasting-refeeding 
treatments or a prolonged high carbohydrate diet, situations during which SREBP-1c 
would be expected to be expressed, exhibited lower induction of lipogenic genes (97). 
11 
 
Therefore, SREBP-1c is crucial for mediating the regulatory effects of insulin on hepatic 
lipogenesis.  
 A multitude of regulatory mechanisms are necessary to maintain lipid 
homeostasis. Nuclear receptors such as the liver X receptor (LXR) are unique ligand 
activated transcription factors that are able to sense lipids and directly influence 
transcriptional regulation. Interestingly, LXR has been demonstrated to regulate SREBP-
1c and thus likely contributes to the control of hepatic lipogenesis as well. LXR deficient 
mice were found to have decreased hepatic SREBP-1c expression. When treated with the 
LXRα agonist, T0901317, LXR deficient mice did not exhibit an induction in hepatic 
lipogenic genes compared to control mice (98). LXR is considered an intermediary 
component of the insulin-sensing pathway as insulin treatment resulted in the induction 
of LXRα mRNA as observed in both in vitro and in vivo studies (99). LXR has a 
comprehensive regulatory role over many components of the lipogenesis pathway and 
will therefore be the primary focus of my thesis.  
1.3 The liver X receptor  
1.3.1 Overview of the liver X receptor  
 The liver X receptors (LXRα and LXRβ) are nuclear receptors that are involved 
in the regulation of cholesterol, lipid and glucose homeostasis (100).  LXR is located 
within the nucleus and heterodimerizes with the retinoid X receptor (RXR) upon 
activation (101). LXR is regarded as a permissive nuclear receptor as either LXR or RXR 
ligands can activate the dimer (102-104). Although LXRα and LXRβ isoforms share 
approximately 77% homology, they differ in their expression profiles (105).  LXRα is 
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predominantly expressed in the liver, intestines, kidney, spleen and testes (106), while 
LXRβ is ubiquitously expressed in the body (101, 106, 107). LXR/RXR heterodimers 
bind to specific LXR binding element motifs (LXRE) in the promoter of genes, which 
consist of direct repeats (DR-4) of the AGGTCA sequence separated by 4 nucleotides 
(101).  
1.3.2 LXR and cholesterol synthesis 
 The discovery of the endogenous activators of LXRα helped to elucidate the 
biological role of this nuclear receptor. Early studies demonstrated that oxysterols such as 
24(S)-hydroxy-cholesterol and 22(R)-hydroxycholesterol lead to the activation of LXRα 
(104, 108). Upon ligand binding, LXRα was observed to bind to the cholesterol 7α- 
hydroxylase promoter (CYP7A), the rate-limiting enzyme in cholesterol catabolism. 
These data provided early indication of the role of LXRα in cholesterol homeostasis, 
specifically the conversion of cholesterol to bile acid (104, 108, 109). Gene knockdown 
studies in mice have since demonstrated that when challenged with a cholesterol rich diet, 
LXRα deficient mice are unable to catabolize excess cholesterol and experience less bile 
acid synthesis compared to control mice. In addition, there was no compensatory effect 
by LXRβ, further confirming differential gene expression regulation by the LXR 
isoforms (110). Oxysterol binding to LXRα leads to the activation of other targets such 
as ATP-binding cassette transporter 1 (ABC1) and inhibits low-density lipoprotein 
receptor (LDLR) involved in cholesterol efflux and uptake, respectively (111-113). 
Therefore, LXRα was originally characterized as a cholesterol sensor in the maintenance 
of cholesterol homeostasis.  
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 Interestingly, LXRα deficient mice also exhibited changes related to other hepatic 
pathways including fatty acid synthesis. Key enzymes and factors in the fatty acid 
biosynthetic pathway such as SCD-1, FAS and SREBP-1c, were down regulated in the 
liver of knockout mice. Furthermore, increased lipid deposits in the liver observed in the 
liver of deficient mice implicate a broader role of LXRα (110).  
1.3.3 LXR and fatty acid synthesis 
 In addition to SREBP-1c, LXRα has been implicated to play a direct role in 
hepatic fatty acid synthesis (114, 115). LXR deficient mice exhibited decreased plasma 
triglyceride levels and free fatty acids concomitant with depressed fatty acid synthesis 
rates between 60-80% (100). Studies using potent nonsteroidal LXRα agonists such as 
T09013177 and GW3965 have helped characterize the regulatory role of LXRα (115, 
116).  Notably, both synthetic agonists are highly selective for LXR α and β over several 
other nuclear receptors including, RXR and constitutive androstane receptor (CAR) (115, 
116). Small animal studies have demonstrated that treatment with T0901317 led to 
significant increases in plasma triglyceride levels, which was associated with an 
induction in the activity of FAS, ACCα, SCD-1 and SREBP-1c in mice and hamsters. To 
further elucidate the role of LXRα in fatty acid synthesis, LXR deficient mice treated 
with LXRα agonist found that animals exhibited blunted expression of fatty acid 
biosynthetic genes compared to wild type mice (115). Thus, another layer of fatty acid 
regulation by LXR was uncovered.  
 However, it remained unknown whether LXRα had a direct and separate 
regulatory role from SREBP-1c. An in vitro model demonstrated that the treatment of 
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TPH-1 macrophages with LXR agonists T0901317 or GW3965 led to the activation of 
LXR and increased FAS mRNA expression despite the active suppression of SREBP-1c 
expression (117). Moreover, a temporal relationship was observed in LXRα agonist 
treated mice as triglyceride levels increased with rising FAS gene expression. Therefore, 
it was determined that LXRα was able to directly activate FAS and contribute to 
increased triglyceride production in a SREPB-1c independent manner (117). From these 
experiments, an LXRE was identified between -669 and -655 base pairs (bp) in the rat 
FAS promoter, which is also highly conserved in humans (118). Similarly, SREBP-1c has 
also been shown to bind directly to highly conserved tandem sites between -71 and -54 
bp in the rat FAS promoter (119). With the existence of both binding sites, luciferase 
activity assays have demonstrated that the activation of both LXRα/RXR and SREBP-1c 
leads to the additive activation of FAS (117). LXRα has been established to directly and 
indirectly control hepatic fatty acid synthesis. 
 Likewise, LXR is able to directly target additional enzymes along the fatty acid 
synthesis pathway. Studies eliminating SREBP-1c expression, found that treatment with 
an LXR agonist in mice results in an increase in MUFAs and triglycerides via the 
activation of SCD-1 expression. Furthermore, researchers have identified an LXR 
binding site in the mouse promoter of SCD-1 between positions -1263 and -1248 bp 
(120). LXR can also directly interact with the promoter of ACCα between -101 and -71 
bp. Similarly, LXR agonist treatment led to an increase in ACCα mRNA expression 
independent of SREBP-1c binding in chick embryos (121). This is of importance as 
changes in ACCα expression are vital in overall triglyceride levels (121). In summary, 
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LXR-mediated changes in fatty acid synthesis can lead to significant downstream 
alterations in triglyceride levels.  
1.3.4 LXR and glucose regulation  
 In contrast to the activating role of LXR in cholesterol and fatty acid homeostasis, 
LXR plays a suppressive role in the regulation of hepatic glucose metabolism (122).  
Studies have demonstrated in mice treated with LXR agonist GW3965, resulted in the 
upregulation of hepatic lipogenic targets while repressing peroxisome-proliferator 
activate-receptor coactivator-1 (PGC-1), a transcriptional coactivator necessary for the 
activation of a plethora of hepatic gluconeogenic genes (123, 124). While my thesis 
focuses mainly on fatty acid synthesis, LXR activation can lead to coordinated glucose 
regulation in adipose tissue and skeletal muscle (122, 125). Studies demonstrate that 
GW3965 treated mice exhibit increased Glut4 mRNA levels in adipose tissue, while 
T0901317 treatment in human myotubes leads to increased glucose uptake (122, 125). 
Together, these studies suggest that LXR activation helps to maintain glucose levels by 
promoting peripheral glucose uptake while suppressing gluconeogenesis in the liver. 
LXR may be the key link in the control of lipid and glucose metabolism whereby LXR 
limits the production of glucose in the liver while promoting glucose uptake and 
stimulating de novo lipogenesis for storage of excess energy as triglycerides in adipose 
tissue (122). Furthermore, treatment with an LXR agonist has been shown to improve 
glucose tolerance in mouse models of obesity and insulin resistance (122). Although 
modulation of LXR activity would appear to be a promising therapy for the treatment of 
diabetes and hyperglycemia, it is important to resolve and balance the impact of LXR 
regulation on fatty acid and cholesterol homeostasis as well.  
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1.4 Epigenetics  
1.4.1 Overview of epigenetics  
 In recent years epigenetics has emerged as a dynamic form of regulation that 
relies on the information that is held in how the genome is packaged. Although various 
definitions of epigenetics have been put forth, it is broadly defined as the structural 
adaptations of chromosomal regions that can signal altered states of activity (126). 
Therefore, transcription can be turned “on” or “off”, depending on the packaging of 
genes (127).  
DNA is wrapped around an octamer of histones, consisting of two copies of 
histones H2A, H2B, H3 and H4 to form a nucleosome, the main packing element of 
genomic DNA (128, 129). DNA binding to histones is facilitated through an electrostatic 
interaction between the positively charged peptides and negatively charged DNA 
backbone (130). Nucleosomes are linked together by 10 to 60 bp of DNA that are 
associated with histone H1 to form higher order chromatin structures (131). Histones 
possess N- (NH2-) and C-terminus (COOH-) tails that emanate out of the nucleosome 
and are susceptible to covalent modifications such as methylation, acetylation, 
phoshorylation, ubiquinitination and ADP-ribosylation (127, 131, 132). Alterations to 
histones can lead to large functional modifications in transcription, revealing a “histone 
code” that confers states of transcriptionally silent heterochromatin and active 
euchromatin (127, 133, 134).  
  
 
 
1.4.2 Histone acetylation 
 One of the first pieces of evidence of the histone code 
histone acetylation results in an increase in RNA synthesis
that an increase in histone acetylation preceded an increase in RNA and protein synthesis 
in human lymphocytes (135)
transition to transcriptionally active chromatin by increasing the accessibility of gene 
templates to transcription factors, which are inhibited by the structure of the nucleosome
in the absence of acetylation
reducing the number of positive charges and disrupting the uniform charge distribution of 
Fig. 1.4.1 Overview of the role of posttranslational histone modifications (acetylation 
and methylation) in transcriptional regulation 
 
was demonstrating that
 (133). Early studies observed 
. Histone acetylation has since been found to dictate the 
 (136). Histone acetylation increases accessibility by 
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positively charged lysine and arginine residues of histone amino tails (130). For that 
reason, the stability of DNA wrapped around peptides has been found to be five times 
less stable and possess a greater number of uncoiled base pairs compared to non-
acetylated peptides (130, 137). Histone acetylation commonly occurs on the N-terminal 
of histones H3 and H4, as studies have demonstrated that replacement of N-terminal 
residues silences the effects of histone deacetylases (HDAC) (138-140). Histone 
deactylases such as the family of sirtuin enzymes facilitate the removal of acetyl groups 
and contribute to the formation of heterochromatin (141).  
 Among the known posttranslational modifications, acetylation and deacetylation 
have garnered the most attention (142). Enzymes, namely histone acetyltransferases 
(HAT), are responsible for the acetylation of histone tails. HATs were found to possess 
domains that were homologous for yeast adaptor proteins indicating that 
acetyltransferases are also recruited in a gene specific manner (143, 144). HATs are 
classified based on their function: A-type are involved in transcription whereas B-type 
are involved in nucleosomal assembly. For example, p300/CBP are A-type HATs that 
have been found to interact with many DNA-binding transcriptional factors (145).  
1.4.3 Histone methylation  
 Histone methylation is a common posttranslational modification that is commonly 
associated with the inhibition of gene expression (146). Histone methylation mediates 
transcriptional silencing by acting as a signal for the recruitment of repressive complexes 
that leads to deacetylation (147, 148). Methylation commonly occurs at lysine or arginine 
residues on histones H3 or H4 in a mono-, di- or tri-methylated manner (149). Since the 
discovery of histone methylation as a regulatory signal, several histone 
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methyltransferases (HMT) have been characterized. For example, the human SUV39H1  
possesses catalytic activity and demonstrates site preference for methylation at the N-
terminal of histone H3 (150).   
1.4.4 Epigenetics and fetal programming  
 To date, there is very little data on the epigenetic regulation of LXR target genes. 
However, studies have begun to reveal evidence of altered gene activation due to 
posttranslational histone modifications. Treatment of chick embryos with LXR agonist 
T0901317 led to a direct increase in ACCα mRNA expression increased LXR binding to 
the LXRE within the 5’ upstream region of ACCα and enhanced acetylation of histone 
H3 (151). In a similar fashion, treatment with T0901317 in human hepatocellular 
carcinoma cell line (HepG2) led to an enrichment of histones H3 and H4 acetylation at 
the LXRE of the FAS promoter. Further experiments showed that histone acetylation was 
diminished in LXRα deficient cells, suggesting that LXRα expression was required for 
these histone modifications (152). Although lipogenic genes can be subjected to 
posttranslational histone modifications, it has yet to be concluded if chromatin 
remodeling is associated in models of fetal programming. Our laboratory has begun to 
shed light on permanent epigenetic changes due to insults during perinatal life. We have 
previously shown that maternal protein restriction (MPR) through pregnancy and 
weaning leads to long-term hypercholesterolemia in rat offspring as a result of impaired 
Cyp7a1 expression, an LXR target gene (153). This decreased Cyp7a1 expression was 
influenced by diminished acetylation and increased methylation at the LXRE of the 
Cyp7a1 gene, promoting a repressive chromatin environment that persisted into 
adulthood (153). Recently, we have also shown that MPR during pregnancy alone leads 
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to the suppression of LXRα expression long-term due to decreases in the acetylation of 
histone H3 [K9,14] and RNA polymerase II recruitment surrounding the proximal 
promoter (-144 to +134 bp) of the LXR gene (154). Additionally, our laboratory has 
explored the posttranslational modifications that occur in response to maternal hypoxia 
during gestation in rat offspring. We demonstrated that maternal hypoxia led to decreased 
glucose-6-phosphatase (G6Pase) mRNA and protein expression, concomitant with 
increased methylation of histone H3 [K9] at the LXRE of the G6Pase promoter in 12 
month old rat offspring (155). Our work supports that multiple models of fetal 
programming are associated with posttranslational histone modifications of hepatic LXR 
target genes and will continue to be explored in our model of MNE.  
1.5 Developmental origins of health and disease (DOHaD)  
1.5.1 History of DOHaD 
 Epidemiological data has demonstrated that poor fetal growth is strongly 
correlated with various long-term developmental alterations in offspring including 
increased risk for cardiovascular disease (156), high blood pressure (157), type two 
diabetes (158, 159), and raised fasting serum triglyceride levels (160). It is important to 
note that these relationships were found independent of confounding factors such as 
alcohol consumption and social class of mothers, strengthening the studies supporting 
DOHaD.   
 Early evidence of DOHaD in humans was observed during the Dutch famine, an 
acute period of exposure to suboptimal nutrition. Studies examining this period of history 
discovered that children exposed to poor nutrition in utero experienced decreased glucose 
tolerance in later life (161). Similar studies in England found that low birth weight was 
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associated with an increase in mortality from CV disease in adulthood (156, 162). 
Growing evidence has supported the idea that developmental adaptations made in utero, 
may lead to permanent changes or “programming” of the body (163). To help 
characterize this phenomenon, Hales and Barker put forth “The Thrifty phenotype 
hypothesis”. They proposed that the in utero environment provides cues of the postnatal 
environment for the fetus, which causes the fetus to make thrifty adaptations for survival. 
However, these once advantageous changes become detrimental if the postnatal 
environment differs from the cues established in utero (158).  
 Since the conception of DOHaD, a wide range of adverse intrauterine 
environments including alterations in oxygenation and hormone levels have been linked 
to increased incidence of CV and metabolic disease in adult life (164).  
1.5.2 Models of fetal programming  
 Animal models have helped to elucidate the mechanisms underlying DOHaD, and 
shed light on the nature of the insult, timing and duration that lead to specific 
physiological outcomes (164). Rodent models have demonstrated that even minor 
changes in protein intake throughout pregnancy and lactation can lead to long-term 
hypercholesterolemia in rat offspring (153). Furthermore, our laboratory has 
demonstrated that MPR during gestation alone results in glucose intolerance in later life 
(165). These studies revealed that the manifestation of features of the metabolic 
syndrome in offspring does not solely rest on the type of insult, but the duration of the 
insult in perinatal life. Other nutritional insults explored in animal models of fetal 
programming include iron deficiency, high fat diet and micronutrient deficiencies (166-
168).  
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 Stress-related increases in glucocorticoids during pregnancy have been linked to 
low birth weight and higher fasting plasma glucose levels in adult rat offspring (169, 
170). Long-term programming, studies have demonstrated that 20 year old individuals, 
who were all low birth weight, had higher cortisol levels compared to individuals who 
were deemed appropriate weight for gestational age (171). This suggests that the 
hypothalamaus-pituatary–adrenal axis could be susceptible to programming changes in 
utero (171).  
 Hypoxia is a common consequence of placental insufficiency and has also been 
implicated in the fetal programming of adult disease (172). Chronic maternal hypoxia 
exposure in a rodent model has been shown to lead to decreased relaxation of mesenteric 
arteries and increased risk for ischemic injury in adult life (173, 174). In concordance 
with hypoxia-induced CV dysfunction, maternal hypoxia can also lead to permanent 
impairments in glucose homeostasis. Livers of adult male rat offspring exposed to 
hypoxia during gestation alone exhibited decreased G6Pase expression, an enzyme 
necessary for the progression of the glycolytic pathway (155, 175). Consequently, 
exposure to chronic maternal hypoxia can predispose offspring to a variety of disorders in 
adulthood.  
 Although catch-up growth may not be a tangible in utero insult, it is nonetheless a 
contributor to the fetal programming phenomenon. Catch-up growth is defined as a 
child’s return to their genetic growth trajectory after experiencing a period of slowed 
growth (176). For example, following MPR in rats, offspring that are fed a high caloric 
diet in postnatal life have a propensity to catch up in weight and then continue to become 
overweight compared to control rats (177).  Similarly, children who experienced catch up 
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growth between the ages of 0 and 2 years old, were more likely to have increased body 
mass index (BMI) and fat mass at 5 years of age compared to other children their age 
(176). Although it is generally accepted that regardless of age, an association exists 
between rapid growth and being overweight as an adult (178), the underlying molecular 
mechanisms are not well characterized.  
 In summary, human and animal studies have clearly established that physiological 
changes that occur in response to the maternal environment in fetal and neonatal life can 
impact an individual’s health long-term. Further understanding of the critical windows of 
DOHaD could lead to novel therapies for the prevention of a variety of adult onset 
diseases.  
1.5.3 Fetal programming models of MNE 
 Animal models of MNE have been critical in understanding the effect of nicotine 
exposure alone. Numerous studies on both smoking and nicotine have explored 
alterations in brain, lung and reproductive outcomes in offspring (179-184). More 
recently, MNE studies indicate that nicotine alone could be linked to the development of 
features of the metabolic syndrome such as obesity (185).  
 Given the neurological risks observed in children of smoking mothers, animal 
models have been imperative in investigating this underlying association. Rats exposed to 
the equivalent amount of nicotine as smoking 3 packs per day via an osmotic pump, 
exhibited a decrease in the number of rat fetal brain cells. Furthermore, it was found that 
exposure to nicotine resulted in a delay in cerebellum maturation in rat offspring (186). 
Using a similar method of nicotine delivery during pregnancy, one study observed an 
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increase in the stimulation of cholinergic activity in the cerebral cortex of rat offspring 
(187). This increased activity may lead to premature stimulation and disruptions to the 
normal timing of postnatal brain development (187). In conjunction with developmental 
impairments, prenatal nicotine exposure has been shown to influence behavioural 
outcomes in offspring as well. Rat offspring exposed to nicotine in utero, were observed 
to be more anxious and poorer adaptors compared to control offspring at PND45 (188). 
These studies link nicotine as a critical component of cigarette smoke to the development 
of neurological impairments in children exposed to smoke during pregnancy.   
 Children of smoking mothers also share strikingly similar compromises in lung 
development and function observed in animal models of MNE (189). In rhesus monkey 
and rodent studies of MNE during pregnancy, offspring were observed to have increased 
collagen deposition around large airways, a potential precursor to lung fibrosis, in 
newborn and 3 month old offspring, respectively (189, 190). Newborn monkeys exposed 
to nicotine in utero also suffered significant impairment to lung development, decreased 
function capacity and increased pulmonary resistance.   
 Interestingly, epidemiological evidence has now linked in utero exposure to 
tobacco and the development of obesity in children (191). A variety of windows of 
nicotine exposure have resulted in a spectrum of obese-related outcomes in offspring. 
Nicotine exposure during pregnancy via the implantation of nicotine osmotic minipumps 
in rats led to both early- and long-term alterations in rat offspring. During early neonatal 
life, MNE rat offspring exhibited increased white adipose tissue and adipocyte 
hypertrophy. Subsequently, these offspring continued to develop insulin resistance in 
adulthood (185).  
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 Notably, our rat model of maternal nicotine exposure during pregnancy and 
lactation (MNE-PL) has already been found to lead to increased bodyweight, adiposity, 
blood pressure, β-cell loss, impaired fecundity and glucose homeostasis long-term in 
offspring (192-196). Importantly, this animal model is highly relevant to the human 
population as the amount of nicotine used is equivalent to the amount of nicotine children 
of average smokers are exposed to (192). In our rat model of MNE-PL, the dose of 
nicotine results in maternal cotinine concentrations comparable to moderate smokers (80-
163ng/ml) and concentrations of cotinine measured in offspring that are within the range 
(5-30ng/ml) observed in infants nursed by smoking mothers (192, 197, 198). 
Furthermore, previous studies of this model of MNE-PL found there was no effect on 
maternal food intake, eliminating maternal obesity as a confounding variable in the long-
term programming of metabolic dysfunction in rat offspring (10, 192).  
 Surprisingly, some nicotine-induced developmental changes have been 
transgenerational. Second-generation offspring of dams exposed to nicotine during 
pregnancy and lactation, developed perturbations in blood pressure and insulin levels 
despite the fact that these offspring were not directly exposed to nicotine themselves 
(194, 199).  In humans, limited data exists on the impact of a mother’s exposure to 
smoking in utero on her children. One study has demonstrated that a smoking mother 
exposed to smoke in utero, is more likely to have a lighter child compared to a smoking 
mother who had not been exposed to smoke in utero (200). 
1.6 Thesis hypothesis and objectives  
 Smoking during pregnancy is associated with numerous fetal and neonatal 
complications short-term, along with increased risk of adult-onset diseases. While 
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nicotine replacement therapy is widely prescribed in pregnancy as a pharmacotherapy for 
smoking cessation, there is little information to date on the effects of maternal nicotine 
exposure on long-term diseases processes. Animal studies suggest that nicotine exposure 
alone during fetal and neonatal life may increase the risk of dyslipidemia and obesity in 
postnatal life. This study aimed to investigate the permanent changes in liver function, 
which may mediate in part the etiology of metabolic dysfunction rat offspring exposed to 
nicotine during pregnancy and lactation.  
Hypothesis:  
 We hypothesize that maternal nicotine exposure during pregnancy and lactation 
will lead to long-term liver dysfunction in the offspring.  
Objectives:  
1) To determine whether maternal nicotine exposure during pregnancy and lactation leads 
to changes in expression of hepatic fatty acid biosynthetic enzymes in rat offspring.  
2) To examine the underlying transcriptional mechanisms and posttranslational histone 
modifications that may be involved. 
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CHAPTER 2 : MATERIALS AND METHODS 
2.1 Maternal nicotine exposure during pregnancy and lactation (MNE-PL) animal 
model  
2.1.1 Animal care and drug administration  
 All animal experiments were performed at McMaster University and were 
approved by the Animal Research Ethics Board at McMaster University, in accordance 
with the guidelines of the Canadian Council for Animal Care. Nulliparous female Wistar 
rats (200-250g, Harlan, Indianapolis, IN, USA) were randomly assigned to receive daily 
subcutaneous injections of saline (vehicle) or nicotine bitartrate (1mg/kg/day, Sigma-
Aldrich, St. Louis, MO, USA) for 2 weeks prior to mating, during pregnancy until 
weaning (PND21) as previously described (195, 201). This dose of nicotine has been 
previously shown to lead to cotinine concentrations in maternal serum (135.9±7.86 
ng/ml) that fall within the range reported of “moderate” female smokers (80-163ng/ml) 
and in serum cotinine concentrations (26.2±1.78 ng/ml) in offspring, that are comparable 
to the range (5-30 ng/ml) found in infants nursed by smoking mothers (45, 192, 195, 
198). Dams were allowed to deliver normally and at PND1 all litters were culled to eight. 
At PND1 and PND21, subsets of male offspring were sacrificed by CO2 inhalation for 
body weight measurements and liver tissue collection. All animals were weighed at 
necropsy. Livers were snapped frozen in liquid nitrogen and stored at -80°C until 
molecular analysis.  
 
 
 A third subset of offspring were caged as sibling pairs and at 
rats were fasted overnight and sacrificed by CO
measurements. Livers were snapped frozen in liquid nitrogen and stored at 
molecular analysis. Blood was collected, allowed to clot, spun and serum was stored at 
80°C until analysis (Fig. 2.1.1)
 
 
 
Fig. 2.1.1 Overview of animal model of maternal nicotine exposure during 
pregnancy and lactation. 
saline (vehicle) for two weeks prior to mating until weaning. Offspring were 
sacrificed at PND1, 21 and 180 for analysis.
PND180, 
2 inhalation for body weight 
. 
Pregnant rats were administered nicotine bitartrate or 
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2.1.2 Plasma and hepatic lipid measurements  
 Total cholesterol, triglyceride and glucose levels were measured from blood and 
hepatic tissue samples using Cobas® analyzer at the Metabolic Phenotype Laboratory at 
Robarts Research Institute (London, Ontario, Canada). Briefly, triglycerides are 
hydrolyzed by lipoprotein lipase to glycerol and fatty acids. Glycerol is then 
phosphorylated to glycerol-3-phosphate by ATP in a reaction catalyzed by glycerol 
kinase (GK). The oxidation of glycerol-3-phosphate is catalyzed by glycerol phosphate 
oxidase (GPO) to form dihydroxyacetone phosphate and hydrogen peroxide (H2O2). In 
the presence of peroxidase, H2O2 alters the oxidative coupling of 4-chlorophenol and 4-
aminsophenazone to form a red-colored quinoneiminse dye, which is measured at 512 
nm. The increase in absorbance is directly proportional to the concentration of 
triglycerides in the sample. 
2.2 Molecular analysis  
2.2.1 Quantitative real-time polymerase chain reaction (qRT-PCR) 
 Total RNA from male and female liver tissue was extracted at PND1, PND21 and 
PND180 by the one-step method described by Chomczynski and Sacchi  (202). RNA was 
treated with deoxyribonuclease to remove any contaminating DNA. 4µg of the total RNA 
was reverse transcribed to cDNA using random primers and Superscript II RNase H-
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Primer sets directed for the genes 
of interest (FAS, ACCα, SCD-1, SIRT-1, p300) were generated using 
OligoPerfect™Designer (Invitrogen, Carlsbad, CA, USA) (Table 2.2.1).  The Bio-Rad 
CFX384 Real Time System was employed to determine quantitative mRNA expression 
using the DNA binding dye SsoFast™ EvaGreen® Supermix (Bio-Rad, Mississauga, 
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Ontario, Canada). The cycling conditions were as follows: 50°C for 2 mins, 95°C for 10 
mins, followed by 45 cycles of 95°C for 15 sec, and 60°C for 1 mins. The cycle threshold 
was set at a level where the exponential increase in PCR amplification was roughly 
corresponding between all samples. The relative fold changes were calculated using the 
comparative cycle times (Ct) method with β-actin as the reference gene. All primer sets 
were demonstrated to have good linear correlation (slope≈-3.4) strongly suggesting equal 
priming efficiency (data not shown). ∆Ct values for each primer set were calibrated to the 
experimental samples with the lowest transcript abundance (highest Ct value). The 
relative abundance of each primer set compared with calibrator was determined by the 
formula, 2∆∆Ct, in which ∆∆Ct is the calibrated Ct value. 
Table 2.2.1 Primer sequences for quantitative real-time PCR analysis  
Gene Primer (5’-3’) Reference No. 
FAS FWD GGA CAT GGT CAC AGA CGA TGA C 
REV  CGT CGA ACT TGG ACA GAT CCT T 
X62889.1 
ACCα FWD TCC GTA TGT GAC CAA AGA CC 
REV  TAC GTT GTT CCC AAG GAC TG 
NM_022193.1 
SCD-1 FWD GCT TGT GGA GCC ACA GGA CTT AC 
REV  ATC CCG GGC CCA TTC ATA TAC 
NM_031841.1 
p300 FWD AGC GAG CTT ATG CTG CTC TC 
REV GGC ACT CAT GTT GTT CAT GG 
NW_001084859.1 
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2.2.2 Protein extraction and western immunoblotting analysis 
 Tissue protein was extracted from snap frozen liver samples using RIPA lysis 
buffer solution (50 mM Tris-HCl, pH 7.4, NP-40 1%, Na-deoxycholate 0.25%, 150 mM 
NaCl, 1mM EDTA, 50 mM NAF, 1mM NaV, 25 mM β-glycerophosphate) and a 
protease inhibitor (Roche). The liver sample was placed in 600 µl of RIPA lysis buffer 
and homogenized with an IKA T10 Basic S1 Dispersing Tool (IKA Works Inc, 
Wilminsgton, NC). The homogenates were placed on ice for 5 mins before rotation at 
4°C for 10 mins. The homogenates were subsequently centrifuged at 300 g for 15 mins at 
4°C. The supernatant was transferred to fresh tubes and centrifuged at 14 000 RPM for 
20 mins at 4°C. The supernatant was retained as the protein preparation. Equal 
concentrations of total protein were normalized using a colorimetric BCA Protein Assay 
(Pierce Corp., Madison, WI, USA). Each loading sample contained 30 µg of protein.  
Samples were fractionated in gradient polyacrylamide gels (Invitrogen, Carlsbad, CA, 
USA) and transferred onto polyvinylidenefidluoride membrane (Millipore, Etobicoke, 
Sirt1 FWD AGC TGG GGT TTC TGT TTC CT 
REV CTG GTT ATG CTC TTG GTG TCT TTC 
NC_005119.3 
β-actin  FWD CAG CCT TCC TTC CTG GGT AT 
REV AGG AGC CAG GGC AGT AAT TCT 
NM_031144.3 
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Ontario, Canada). Blots were probed with FAS (catalog no. 3180S 1:1000, Cell 
Signaling), ACCα (catalog no. 3662S 1:1000, Cell Signaling), LXRα  (cat. no.sc-13068 
1:5000, Santa Cruz Biotechnology), SREBP-1c (catalog no. sc-366, Santa Cruz 
Biotechnology), p-ACCα (catalog no.3661P 1:1000, Cell Signaling) antibodies, and 
monoclonal horseradish peroxidase-conjugated β-actin was used as the housekeeping 
protein (catalog no. A3854 1:50000, Sigma-Aldrich). All antibodies were diluted in 5-7% 
milk-1xTris-buffered saline-Tween 20 (0.01%) buffer. Horseradish peroxidase 
conjugated donkey anti-rabbit IgG (catalog no. 711035152 1:10000, Jackson 
ImmunoResearch Laboratories, West Grove, PA) or horseradish peroxidase conjugated 
donkey anti-mouse IgG (catalog no. 715001003 1:50000) diluted in 5-7% milk-1xTris-
buffered saline-Tween 20 (0.01%) were used as the secondary antibodies. 
Immunoreactive bands were detected using an enhanced chemiluminescence detection 
system (Thermo Scientific, Waltham, MA) and imaged with a VersaDoc Imaging System 
(BioRad). Densitometry analysis was performed using Image Lab Software (BioRad).  
2.2.3  Chromatin immunoprecipitation (ChIP) 
 Chromatin was extracted from liver tissues excised from PND180 male offspring 
as previously described (153). In brief, a small piece of snap frozen liver was 
homogenized in 0.5 mL of 1% formaldehyde and fixed for 10 mins at room temperature 
to cross-link proteins and DNA. Glycine (0.125M, final concentration) was added to all 
samples to terminate cross-linking. Samples were microfuged at 3000 RPM at room 
temperature for 5 mins and supernatant was subsequently discarded. Samples were then 
washed once with cold PBS and spun at 3000 RPM. Supernatant was discarded again and 
500 µl of SDS lysis buffer (Millipore, Etobicoke, Ontario, Canada) with protease 
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inhibitor cocktail (Roche, Mississauga, Ontario, Canada) was added to each sample. 
Samples were incubated for 20 mins at 4°C and then sonicated to produce sheared, 
soluble chromatin. The lysates were diluted ten times with ChIP dilution buffer 
(Millipore, Etobicoke, Ontario, Canada) and aliquoted to volumes of 300 µl. Each of the 
aliquots were precleared with protein A/G Plus agarose beads (20 µl, Millipore, 
Etobicoke, Ontario, Canada) and rotated for 2 hours at 4°C. In order to pellet the beads, 
samples were microfuged at 14000 RPM at 4°C, and the supernatant containing the 
sheared chromatin was retained and placed in new tubes. The aliquots were incubated 
with 3 µg of antibodies against LXRα (cat# sc-13068x, Santa Cruz Biotechnology, Santa 
Cruz, California) or acetylated histone H3 (lysine 9,14, cat #05-399, Millipore, 
Etobicoke, Ontario, Canada) and rotated overnight at 4°C. Two aliquots were reserved as 
‘controls’ – one incubated without antibody (‘input’) and another with non-immune IgG 
(Millipore, Etobicoke, Ontario, Canada). Protein A/G Plus agarose beads (60 µl) were 
added to each tube and then rocked for 1 hour at 4°C. The immune complexes were 
collected by centrifugation. The beads containing the immunoprecipitated complexes 
were washed sequentially for 5 mins in wash buffer I (20 mM Tris-HCl, pH 8.1, 2 mM 
EDTA, 0.1% SDS, 1% Triton X-100, 150 mM NaCl), wash buffer II (same as I, except 
containing 500 mM NaCl), wash buffer III (10 mM Tris-HCl, pH 8.1, 1 mM EDTA, 1% 
NP-40, 1% deoxycholate, 0.25 M LiCl), and twice in Tris-EDTA (TE) buffer. The beads 
were eluted with 250 µl elution buffer (1% SDS, 0.1mM NaHCO3 + 20 µg salmon sperm 
DNA (Sigma-Aldrich, Oakville, Ontario, Canada) at room temperature. The elution step 
was repeated once and eluates were combined. Samples were heated at 65°C for 4 hours 
to reverse the crosslinking of the immunoprecipitated chromatin complexes and ‘input 
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controls’ (10% of the total soluble chromatin). Proteinase K buffer was added to each 
sample (50 mM Tris-Hydrochloride (HCl), pH 8.5, 1% SDS, 10 mM EDTA) and 
incubated for 1 hour at 45°C. The DNA was purified by phenol-chloroform extraction 
and DNA was precipitated overnight at -20°C in 100% EtOH containing 10% sodium 
acetate (pH 5.6). The supernatant was removed and remaining pellets were dried. All 
samples and ‘input’ controls’ were resuspended in 50 µl TE buffer prior to PCR analysis. 
Real-time PCR was employed using forward (5’-GCCACGATGACCGGTAGTAA-3’) 
and reverse (5’-GCGTTGCTAGGCAATAGGGT-3’) primers (PE Applied Biosystems, 
Boston, MA, USA) that amplify a -690 to -561 bp region encompassing the published rat 
FAS LXRE site (118). Using serial dilutions of rat liver chromosomal DNA, the primers 
were demonstrated to have equal efficiency in priming to their target sequences (data not 
shown).  
2.3 Statistics  
 All results are expressed as the mean of arbitrary values ± the standard error of 
the mean (SEM). All results from quantitative qRT-PCR, ChIP and western immunoblot 
analysis were evaluated using an unpaired Student’s t test, where a p value of less than 
0.05 was considered significant. 
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CHAPTER 3 : RESULTS 
3.1 Characterization of offspring exposed to maternal nicotine exposure during 
pregnancy and lactation (MNE-PL)  
3.1.1 Weight responses in male offspring exposed to MNE-PL 
 The birth weights of male MNE offspring were recorded throughout development. 
At PND1, the weights of male MNE offspring were significantly lower compared to 
control (p < 0.05) (Fig. 3.1.1A). At PND21, there was no significant difference in birth 
weight between male offspring exposed to nicotine and control offspring (Fig. 3.1.1B). 
By PND180, an increase in body weight from 563±5g to 605±4g (p<0.001) was observed 
in nicotine-exposed male offspring (Fig. 3.1.1C). This increase in weight is noteworthy 
considering that previous studies in this MNE-PL animal model have demonstrated that 
the growth trajectory of nicotine-exposed offspring was significantly enhanced compared 
to control, while nicotine administration had no effect on gestational length, maternal 
food intake, maternal weight gain or litter size  (196, 201).  
3.1.2 Glucose, cholesterol and triglyceride measurements in control and nicotine 
exposed male offspring 
 MNE-PL led to a significant increase in fasting serum triglycerides in male but 
not female offspring at PND180 (Fig. 3.1.2C). Similarly, hepatic triglyceride levels were 
significantly elevated in male offspring compared to control, although female offspring 
were not examined (Fig. 3.1.2D). Analysis of circulating levels of fasting glucose and 
cholesterol were not significantly altered between control and MNE-PL male offspring at 
PND180 (Fig 3.1.2A-B).  
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Fig. 3.1.1 The effect of maternal nicotine exposure during pregnancy and lactation on 
body weight in male PND1 (A), PND21 (B) and PND180 (C) rat offspring. Results are 
expressed as the mean ± SEM. Nicotine effects were determined using a Student’s t test. 
* = (p < 0.05); n = 6/group. 
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Fig. 3.1.2 The effect of MNE-PL on circulating levels of glucose (A), cholesterol (B), 
triglycerides (C) and hepatic triglycerides (D) in PND180 male rat offspring. Results 
are expressed as the mean ± SEM. Nicotine effects were determined using a Student’s t 
test. For data in Figure 3.1.2C, the t test was performed with the data within each gender. 
* = (p < 0.05); n = 7-17/group. 
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3.2 Long-term effects of MNE-PL on hepatic lipogenic genes in offspring  
3.2.1 MNE-PL increased the steady-state mRNA levels of fatty acid synthesis enzymes in 
the liver of male PND180 offspring  
 In order to elucidate the molecular mechanisms underlying the elevated 
triglyceride levels in nicotine-exposed male adult rat offspring, we next examined the 
hepatic enzymes involved in the fatty acid synthesis pathway leading to de novo 
triglyceride production (85, 87, 88). qRT-PCR revealed significant increases (p<0.05) in 
hepatic fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACCα) mRNA, both 
enzymes involved in the initial steps of fatty acid synthesis, in male (Fig. 3.2.1.1A-B) and 
female (Fig. 3.2.1.2A-B) PND180 MNE-PL offspring (85, 87). Interestingly, no 
significant changes in the hepatic steady-state mRNA levels of stearoyl-CoA 
dehydrogenase 1 (SCD-1) were observed in male (Fig. 3.2.1.1C) or female offspring 
(Fig. 3.2.1.2C).  
 However, due to the lack of significant change in circulating triglyceride levels, 
PND180 female offspring were not further investigated in this study. More importantly, 
this model has been previously demonstrated to exhibit early life programming effects in 
a sexually dimorphic manner, which was not the focus of this investigation (195). 
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Fig. 3.2.1.1 The effect of MNE-PL on hepatic steady-state mRNA levels of FAS (A),
ACCα (B), and SCD-1 (C) in PND180 male rat offspring. RNA was extracted and 
mRNA levels were assessed using qRT-PCR with primers specific for FAS, ACCα and 
SCD-1. Results are expressed as the mean ± SEM. Nicotine effects were determined 
using a Student’s t test. * = p <  0.05); n = 5-10/group.  
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Fig. 3.2.1.2 The effect of MNE-PL on hepatic steady-state mRNA levels of FAS (A),
ACCα (B), and SCD-1 (C) in PND180 female rat offspring. RNA was extracted and 
mRNA levels were assessed using qRT-PCR using primers specific for FAS, ACCα and 
SCD-1. Results are expressed as the mean ± SEM. Nicotine effects were determined using 
a Student’s t test. * = p <  0.05); n = 4-5/group.  
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3.2.2 MNE-PL correspondingly increased the protein levels of hepatic enzymes involved 
in fatty acid synthesis in male PND180 offspring  
 As differences were found in the steady-state mRNA levels of hepatic lipogenic 
genes (e.g. FAS and ACCα), we next performed western immunoblot analysis to 
determine changes at the protein level. At PND180, MNE-PL led to a significant increase 
in FAS protein levels (Fig. 3.2.2.1). Despite changes in mRNA levels, there were no 
corresponding changes in protein levels of ACCα (Fig 3.2.2.2A). Subsequently, the 
inactivated form of ACCα was explored to determine if levels of inactivated ACCα were 
altered due to MNE-PL (203). Western immunblotting revealed no difference in 
phosphorylated-ACCα (Fig. 3.2.2.2B) protein levels between PND180 nicotine exposed 
and control offspring.  
3.2.3 MNE-PL leads to long-term increases in hepatic protein levels of LXRα 
 To begin to decipher the underlying mechanisms behind the increase in FAS 
expression in PND180 male MNE-PL offspring, we next investigated hepatic levels of 
LXRα and SREBP-1c, both regulators of FAS (118, 204). At PND180, MNE-PL led to a 
significant increase in hepatic LXRα protein levels (Fig. 3.2.3A) in male offspring 
compared to control, while no difference was observed in SREBP-1c protein expression 
(Fig. 3.2.3B).  
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Fig. 3.2.2.1 MNE-PL leads to an increase in FAS protein levels in PND180 male 
offspring. Protein was extracted and the expression of FAS was measured using western
immunoblot analysis. The protein levels were quantified using densitometry and 
normalized to the protein levels of a housekeeping protein, β-actin. Results are expressed 
as the mean ± SEM. Nicotine effects were determined using a Student’s t test. * = p < 
0.05); n = 6-7/group.   
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Fig. 3.2.2.2 Exposure to nicotine during pregnancy and lactation does not 
influence ACCα (A) and p-ACCα (B) protein levels in PND180 male offspring. 
Protein was extracted and the expression of ACCα and p-ACCα was measured 
using western immunoblot analysis. The protein levels were quantified using 
densitometry and normalized to the protein levels of a housekeeping protein, β-
actin. Results are expressed as the mean ± SEM. Nicotine effects were determined 
using a Student’s t test. * = p < 0.05); n = 5-7/group.  
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Fig. 3.2.3 MNE-PL leads to an increase in hepatic LXRα protein levels in 
PND180 male rat offspring. Protein was extracted and the expression of LXRα
(A) and SREBP-1c (B) was analyzed using western immunoblot analysis. The 
protein levels were quantified using densitometry and normalized to a 
housekeeping protein, β-actin. Results are expressed as the mean ± SEM. * = p < 
0.05; n= 5-7/group. 
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3.2.4 MNE-PL leads to increased LXRα binding to the putative LXRE on the FAS 
promoter in PND180 male rat offspring  
 The increase in LXRα protein expression suggests that LXRα may be facilitating 
the increase in FAS protein and mRNA expression in adult male offspring exposed to 
nicotine during pregnancy and lactation. To explore this further, we employed chromatin 
immunoprecipitation (ChIP) to examine the in vivo binding of LXRα to its putative LXR 
binding element (LXRE) on the proximal rat promoter (-669 to -665 bp) of FAS (118). 
Real-time primers were designed to surround the LXRE of the FAS gene and were 
demonstrated to equally amplify their target sequences over a range of chromatin 
concentrations (data not shown). While not significant (p=0.13), male PND180 MNE-PL 
offspring in this small samples size (n=5) were observed to have increased LXRα binding 
at the putative LXRE of the FAS promoter (Fig. 3.2.4). Nonimmune IgG displayed 
negligible binding compared to LXRα binding to the FAS promoter.  
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Fig. 3.2.4 MNE-PL increases LXRα binding to the LXRE of the FAS promoter 
in the liver of PND180 male offspring. The in vivo binding of LXR α  to the hepatic 
LXRE of the FAS promoter in male rat offspring at PND180 was assessed by 
chromatin immunoprecipitation. Briefly, cross-linked chromatin was 
immunoprecipitated using an antibody specific for LXR α  and the relative abundance 
of a region surrounding the LXRE (-669 to -655 bp) of the FAS promoter was 
quantified using qRT-PCR. The relative level of immunoprecipitated DNA was 
normalized to total genomic DNA for each sample. The effect of nicotine was 
determined using a Student’s t test. Results are expressed as the mean ± SEM. * = p 
< 0.05; n= 5/group.  
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3.3 Epigenetic alterations of the hepatic fatty acid synthesis pathway in adult rat 
offspring due to MNE-PL  
3.3.1 MNE-PL induced transcriptional activation of hepatic FAS expression is associated 
with an increase in the acetylation of histone H3 [K9,14] surrounding the LXRE of 
the FAS promoter region in PND180 male offspring  
 Since LXRα has been demonstrated to enhance the acetylation of histone H3 
[K9,14] to increase hepatic FAS transcription (152), we next employed ChIP to 
investigate if chromatin remodeling could be a factor influencing the observed increase in 
FAS mRNA and protein levels in MNE-PL offspring. The acetylation of histone H3 [K9, 
14] is well known to be associated with chromatin activation (136). ChIP revealed that 
male MNE-PL offspring in this small samples size (n=5) were trending towards an 
significant increase (p=0.09) in the acetylation of histone H3 [K9,14] surrounding the 
putative LXRE (-669 to -655 bp) of the FAS promoter (Fig. 3.3.1) (118). Nonimmune 
IgG displayed negligible binding compared acetylation of histone H3 [K9,14] 
surrounding the FAS promoter.  
3.3.2 The effects of MNE-PL on the steady-state mRNA levels of histone modifying 
enzymes (Sirt-1 and p300) in the livers of PND180 male offspring  
 As differences were found in the levels of acetylation of histone H3 [K9, 14] 
surrounding the putative LXRE of the FAS promoter, we investigated possible 
mechanisms responsible for the alterations in the epigenetic status of adult male 
offspring. qRT-PCR revealed no difference in mRNA expression of Sirt-1 (Fig. 3.3.2A) 
or p300 (Fig. 3.3.2B), known histone deacetylases and acetyltransferases, respectively 
(141, 145).  
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Fig. 3.3.1 MNE-PL increases the acetylation of histone H3 [K9,14] 
surrounding the LXRE of the FAS promoter in the liver of PND180 male 
offspring. Briefly, cross-linked chromatin immunoprecipicated using an antibody 
specific for acetylated histone H3 [K9,14] was isolated and the relative abundance 
of a region surrounding the LXRE (-669 to -655 bp) of the FAS promoter was 
quantified using qRT-PCR. The relative level of immunoprecipitated DNA was 
normalized to total genomic DNA for each sample. Results are expressed as the 
mean ± SEM. Nicotine effects were determined using a Student’s t test. * = p < 
0.05; n= 5/group.  
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Fig. 3.3.2 MNE-PL does not influence hepatic steady-state mRNA levels of 
Sirt-1 (A) and p300 (B) in PND180 male rat offspring. RNA was extracted and 
mRNA levels were assessed using qRT-PCR with primers specific for Sirt-1 and 
p300. Results are expressed as the mean ± SEM. Nicotine effects were determined 
using a Student’s t test. * = p <  0.05); n = 5/group. 
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3.4 Direct effects of MNE-PL on hepatic fatty acid synthesis in offspring  
3.4.1 The effects of MNE-PL on hepatic fatty acid synthesis in PND1 and PND21 male 
offspring  
 Earlier developmental time points in offspring were examined in order to 
determine whether MNE-PL directly leads to the elevations in triglyceride levels 
observed in male offspring at PND180. qRT-PCR analysis found no differences in FAS, 
ACCα and SCD-1 mRNA levels between PND1 control and MNE offspring (Fig. 
3.4.1.1A-C).  
 Similarly, analysis of FAS, ACCα and SCD-1 mRNA levels via qRT-PCR 
revealed no difference in PND21 male control and nicotine exposed offspring (Fig. 
3.4.1.2A-C). Importantly, the PND21 time point represents the longest period of exposure 
(21 days) to nicotine in offspring.  
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Fig. 3.4.1.1 MNE-PL does not influence hepatic steady-state mRNA levels of ACCα
(A), FAS (B), and SCD-1 (C) in PND1 male rat offspring. RNA was extracted and 
mRNA levels were assessed using qRT-PCR using primers specific for FAS, ACCα and 
SCD-1. Results were expressed as the mean ± SEM. Nicotine effects were determined 
using a Student’s t test. * = p <  0.05); n = 2-5/group. 
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Fig. 3.4.1.2 MNE-PL does not influence hepatic steady-state mRNA levels of ACCα  
(A), FAS (B), and SCD-1 (C) in PND21 male rat offspring. RNA was extracted and 
mRNA levels were assessed using q-RT-PR using primers specific for FAS, ACCα and 
SCD-1. Results are expressed as the mean ± SEM. Nicotine effects were determined 
using a Student’s t test. * = p <  0.05); n = 4-5/group. 
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CHAPTER 4 : DISCUSSION 
4.1 Clinical relevance of the study  
 In this study I present evidence that MNE-PL leads to hypertriglyceridemia in 
PND180 male rat offspring. My data suggests that this effect is due to increased de novo 
hepatic triglyceride synthesis. Specifically, I demonstrated that FAS expression was 
enhanced due to increased LXRα protein levels and binding to the LXRE of the FAS 
promoter in PND180 male MNE-PL offspring. This increase in LXRα binding at the FAS 
promoter was associated with enriched histone H3 acetylation [K9,14] at the LXRE site, 
previously shown to lead to FAS transcriptional activation (152). Given the well-
established link between an adverse in utero environment and the development of 
metabolic dysfunction long-term (158, 205), this study sheds light on possible molecular 
mechanisms that mediate the programming of obesity in children exposed to smoke in 
utero (8). My study also raises questions regarding the safety of NRT during pregnancy 
and long-term consequences for offspring.  
4.2 Examining the mechanisms of nicotine action on hepatic fatty acid synthesis  
 In this thesis, I investigated the influence of MNE-PL on the hepatic fatty acid 
synthesis pathway. I present evidence that MNE-PL leads to elevated levels of hepatic 
and circulating triglyceride levels, concomitant with alterations to fatty acid biosynthetic 
enzyme expression in PND180 male offspring. MNE-PL did not affect circulating 
glucose or cholesterol levels in offspring. My findings support human studies that 
demonstrated adult women exposed to tobacco in utero exhibit elevated triglyceride 
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levels in adulthood (13). Livers of PND1 and PND21 MNE-PL offspring were examined 
to determine whether nicotine directly augments triglyceride levels. These earlier 
developmental time points represent different windows of direct nicotine exposure in 
fetal and neonatal life. PND1 and PND21 MNE-PL offspring did not exhibit any 
significant differences in the expression of FAS, ACCα, or SCD-1 compared to control 
offspring. Consequently my results suggest that elevated triglycerides were not a direct 
result of nicotine exposure, as we would have expected to observe alterations in target 
gene expression at weaning, following the longest window of direct nicotine exposure. 
Moreover, only a subset of primary human hepatic stellate cells express the neuronal 
subunits of nAcHR (α3,α6, α7, β2 and β4) (206). Together, given the lack of nAcHR 
subunit expression in hepatocytes and unaltered fatty acid synthesis in early life, it is 
highly conceivable that nicotine induced alterations in long-term fatty acid synthesis and 
triglyceride levels are a result of indirect mechanisms.  
4.3 Possible mechanisms underlying the effect of MNE-PL on long-term 
programming of hypertriglyceridemia in offspring 
 In this study, MNE-PL resulted in significantly heavier male offspring compared 
to control offspring at PND180. These results support findings from human studies that 
have repeatedly demonstrated an increase in the risk of obesity in children (ages 2 – 33 
years old) exposed to smoking during pregnancy regardless of parental socioeconomic 
background, infant feeding patterns and gestational weight gain (8, 11, 207-210). My rat 
model suggests that nicotine alone leads to the development of obesity and elevated 
triglycerides in children exposed to smoking in utero (209). Despite being heavier in later 
life, I found that MNE-PL offspring at PND1 weigh less compared to control offspring. 
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Children of smoking mothers also shared this surprising characteristic, as exposed 
children are at higher risk for being low birth weight compared to unexposed offspring 
(208, 211, 212). Further studies demonstrate that fetal growth restriction is more likely 
responsible for low birth weight in children rather than preterm delivery (208, 211-213). 
Other animal models of MNE have also proposed that nicotine alone can impair growth 
in offspring. It was found that nicotine injections of 2mg/kg/day during gestation in rats 
led to lower average fetal weight in utero compared to control fetuses (214). Similarly, 
rat offspring exposed to 6mg/kg/day of nicotine during early postnatal life gained 
significantly less weight per day compared to control offspring (215). However, these 
nicotine-exposed pups caught up in size by PND18. While these studies suggest that 
nicotine alone can impair fetal growth, it is important to note that these animal models 
utilized higher concentrations of nicotine compared to the model of MNE-PL used in my 
study. Therefore, future studies should closely monitor the growth of MNE-PL offspring 
to ascertain whether a moderate dosage of nicotine for a longer period of time lead to 
comparable growth impairments in offspring.  
 To resolve the two extreme phenotypes that are observed in response to nicotine 
exposure in perinatal life, my data suggests that MNE-PL offspring undergo catch up 
growth. A study  has demonstrated that babies of smoking mothers tended to be lighter at 
birth but caught up in weight to children of non-smoking mothers by 12 months of age 
(216). Specifically, male children caught up at a faster rate compared to female children 
(216). Furthermore, children that were born small and were able catch up in bodyweight 
had higher percentages of body fat and increased BMI in early life compared to other 
children (176). Therefore, catch up growth may program offspring to overshoot normal 
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growth trajectories leading to a higher likelihood of developing characteristics that are 
predictive of adult obesity (176). Although the mechanisms by which children are able to 
catch up in growth are largely unknown, it has been postulated that low leptin levels in 
low birth weight babies may signal for greater food intake (176). The connection between 
catch up growth and differences in nutritional intake has been investigated by comparing 
breast-fed and formula fed preterm babies. Formula fed babies were found to experience 
high neonatal growth during the first 2 weeks following birth and this was associated 
with higher markers of insulin resistance and an atherogenic lipoprotein profile that was 
observed up to 16 years later (217, 218). Since catch up growth in babies was found 
irrespective of birth weight, researched proposed that the programming of metabolic 
outcomes largely occurs antenatally. Therefore in this study, MNE-PL may impair fetal 
development leading to subsequent catch growth and the programming of 
hypertriglyceridemia in offspring.  
4.4 Catch up growth and ER stress 
 Interestingly, our laboratory has demonstrated that rat offspring exposed to an 
adverse in utero environment followed by rapid catch up growth in postnatal life, exhibit 
increased ER stress (219). Various insults such as glucose deprivation, changes in 
oxidation-reduction balance, infection and development of secretory cells can all lead to 
the misfolding of proteins and initiate the unfolded protein response (UPR) (220, 221). 
The UPR response helps cells cope with an overloaded ER by decreasing translation, 
increasing efflux and stimulating the degradation of proteins (220). The UPR leads to the 
phosphorylation of the eukaryotic initiation factor 2α (eIF2α), which leads to the 
attenuation of further translation (220). It also increases chaperone protein levels (e.g. 
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glucose regulated proteins Grp78 and Grp94) to facilitate increased folding and induces 
the splicing of the X-box binding protein (Xbp-1) to increase protein degradation (220). 
ER-stress induced apoptosis is activated if a cell is overwhelmed by the amount of  
misfolded protein (221). Specifically, our laboratory has demonstrated that postnatal 
catch up growth is associated with elevated levels of ER chaperone protein Grp78 and 
enhanced phosphorylation of eIF2α long-term (219). Since our MNE-PL model appears 
to lead to catch up growth in offspring, future studies should investigate whether hepatic 
ER stress pathways are activated in conjunction with alterations in fatty acid and 
triglyceride synthesis.  
 The role of ER stress in models of catch up growth is an attractive mechanism to 
explain in part, the underlying mechanisms of fetal programming. Indeed, studies have 
already postulated that obesity induces hepatic insulin resistance through elevated ER 
stress signaling in the liver of rodent models (222, 223). Notably, my preliminary data in 
PND180 male offspring exposed to MNE-PL, exhibited increased Grp78 protein levels 
(Fig. 4.4).  
 Yet, the involvement of ER stress in the long-term programming of 
hypertriglyceridemia in nicotine-exposed offspring has not been fully elucidated. 
Although nicotine did not have a direct effect in my MNE-PL model, it would be 
interesting to assess if nicotine could directly induce ER stress in PND1 or PND21 
offspring, or if ER stress is activated due to catch up growth. It is noteworthy that one 
study has demonstrated that antagonism of LXRα protects against steatosis by decreasing 
ER stress (224). This study presents a novel mechanism by which ER stress mediates the 
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development of liver pathology through LXRα activation. Given the increase in LXRα in 
MNE-PL offspring and the association between ER stress and catch up growth, future 
studies will evaluate ER stress markers in the liver of PND180 male offspring. It is 
plausible that nicotine induced ER stress may be causing permanent changes in hepatic 
function via the aberrant activation of LXRα in MNE-PL offspring.  
 
 
 
 
 
 
Fig. 4.4 MNE-PL leads to increased Grp78 protein expression in PND180 male 
offspring. Protein was extracted and the expression of Grp78 was measured using 
western immunoblot analysis. The protein levels were quantified using 
densitometry and normalized to the protein levels of a housekeeping protein, β-
actin. Results are expressed as the mean ± SEM. Nicotine effects were determined 
using a Student’s t test. * = p < 0.05); n = 8/group.   
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4.5 Molecular mechanisms underlying elevated triglycerides in adult MNE-PL 
offspring 
 The three main sources of free fatty acids used for triglyceride synthesis in the 
liver include de novo, circulating, and dietary (87). Human and animal studies have both 
demonstrated that alterations in fatty acid synthesis lead to impairments in triglyceride 
homeostasis (87, 115, 118, 225). In the present study, I have demonstrated elevations in 
the steady-state mRNA levels of FAS and ACCα in the liver of male MNE-PL offspring 
at PND180. MNE-PL offspring also exhibited a corresponding increase in FAS protein 
expression suggesting that alterations in FAS play a central role in de novo triglyceride 
synthesis. Studies in rodent models of obesity associated with elevated plasma 
triglyceride levels, have similarly demonstrated an increase in hepatic FAS protein 
expression (226, 227). Moreover, de novo fatty acid synthesis is considered a dynamic 
process as human studies have shown that the rate synthesis can be drastically altered in 
various disease states (228, 229). Taken together, these data suggest that nicotine 
exposure may permanently increase triglyceride levels, in part, via a FAS-dependent 
pathway.  
 To date, I have only examined de novo triglyceride synthesis as the main source 
for elevated triglycerides observed in PND180 MNE-PL offspring. However, other 
mechanisms could be contributing to the development of hypertriglyceridemia in nicotine 
exposed offspring including differences in food consumption and adipose tissue 
distribution. Since high carbohydrate diets have been shown to increase de novo fatty 
acid synthesis and plasma triglyceride levels in both rodents and humans, future studies 
should closely monitor post-weaning food consumption in nicotine-exposed offspring 
(230-232). In addition, obtaining adipose tissue from MNE-PL offspring will also be 
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pursued in later studies, considering elevated amounts of body fat is a predictor of 
triglyceride levels in humans (233).  
 Given the increase in expression of fatty acid biosynthetic genes, I next 
investigated changes in regulatory mechanisms. The expression of FAS is under the 
direct control of various transcription factors including LXRα (-669 to -655 bp), SREBP-
1c (-71 to -54 bp), and ChREBP (-7214 to -7190 bp) (117, 119, 234). My study 
determined that there were significantly higher levels of LXRα protein in MNE-PL 
offspring compared to control offspring. In parallel, unpublished data from our laboratory 
has demonstrated that following short-term neonatal exposure to an LXR agonist leads to 
higher triglycerides levels in rat offspring (Fig. 4.5). Models involving treatment with 
LXRα agonists have demonstrated similar elevations in plasma triglycerides along with 
an induction of hepatic FAS expression (118). Likewise, LXR deficient mice treated with 
LXRα agonist do not exhibit an increase in triglyceride levels (204). Therefore, LXRα 
activation is imperative to FAS activation and triglyceride synthesis.  
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Fig. 4.5 Treatment with LXR agonist, GW3965, during pregnancy in rats led 
to increased circulating triglyceride levels in offspring. Results are expressed as 
the mean ± SEM. LXR agonist effects were determined using a Student’s t test. * = 
(p < 0.05); n = 6-9/group.  
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 To determine whether the increase in LXRα and its target, FAS, were 
functionally related, ChIP experiments were carried out to measure in vivo binding of 
hepatic LXRα to the promoter of FAS in PND180 male offspring. ChIP studies revealed 
increased LXRα binding surrounding the putative LXRE (-669 to -655 bp) of the FAS 
promoter (117). My results suggest that an elevation in hepatic LXRα expression 
mediates the transcriptional activation of FAS. Remarkably, other models of fetal 
programming have demonstrated that LXR and LXR-target genes are susceptible to 
permanent programming changes (153, 155, 235). Thus, it is conceivable that nicotine-
mediated changes in triglyceride levels are occurring in part through prolonged or even 
permanent increase in FAS activation. It would be interesting to further ascertain the role 
of LXRα in modulating permanent elevations in FAS expression by undertaking in vitro 
studies. In vitro studies involving the treatment of hepatocytes with LXRα antagonists 
such as piperine, followed by the analysis of FAS expression and ChIP analysis would 
help confirm whether permanent FAS activation in MNE-PL offspring is attributed 
directly to LXRα (224).  
 While it has been established that LXRα plays a large role in the regulation of 
FAS, other regulatory pathways should be considered in future studies. SREBP-1c is a 
transcription factor that is activated in its cleaved form and inhibited in the presence of 
sterols (119, 236, 237). Similar to LXRα, SREBP-1c can directly activate certain fatty 
acid biosynthetic enzymes including FAS, ACCα and SCD-1 (119, 238, 239). In my 
study I found no difference in SREBP-1c protein expression between PND180 MNE-PL 
and control offspring. My findings support previous studies demonstrating augmented 
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triglyceride levels in obese mice despite diminished SREBP-1c expression (240). For this 
reason, SREBP-1c is considered an auxiliary regulator of fatty acid synthesis that is under 
the direct control of LXRα (115, 236). Future studies could investigate the carbohydrate-
responsive element binding protein (ChREBP). ChREBP is a transcription factor from the 
same family as SREBP-1c that heterodimerizes with the protein Max-like protein X 
(Mlx) (241). It binds to carbohydrate response elements (ChoRE) of glucose responsive 
targets found throughout the de novo lipogenic pathway (241, 242). ChREBP is 
ubiquitously expressed, with the highest expression found in the liver, brown and white 
adipose tissues, small intestine, kidneys and muscle (242). ChREBP knock-out mice 
exhibited lower levels of hepatic FAS and ACCα and a 65% decrease in fatty acid 
synthesis rates compared to control mice. Importantly, there were no changes in SREBP 
levels, meaning that the loss of ChREBP was not mediated via SREBP-1c (242). 
Consequently, ChREBP is another independent regulatory mechanism that should be 
considered for future investigation in adult MNE-PL male offspring.  
4.6 The role of epigenetics in the fetal programming of hypertriglyceridemia in adult 
MNE-PL offspring  
 In this present study, I have demonstrated an increase in acetylation of histone H3 
surrounding the LXRE of the hepatic FAS gene in PND180 MNE-PL offspring. My 
findings suggest that maternal nicotine exposure leads to long-term posttranslational 
histone modifcations that facilitate increased transcription of FAS. While my results 
demonstrate changes in chromatin remodeling due to MNE-PL, the effect of nicotine on 
epigenetic changes is virtually unknown. In vitro studies in primary neuronal cortical 
cells and primary human lymphocytes have shown that nicotine exposure leads to a more 
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transcriptionally ‘permissive’ chromatin environment through alterations in the 
expression of HMTs such as GLP, G9a and Setdb1 (243). Similar histone modifications 
were observed in vivo. A single intraperitoneal injection of 3mg/kg of nicotine was able 
to elicit measurable changes in mouse cortical extracts 6 hours following injection (243).  
It would be interesting to determine whether measurable changes occur in methylation 
and HMT expression in my model of short-term neonatal exposure to nicotine. Future 
studies should investigate all developmental time points  (PND1, 21 and 180) in MNE-PL 
offspring, to examine whether MNE results in posttranslational histone modifications that 
precede the development of long-term hypertriglycerdemia in offspring.  
 Lastly, mRNA levels of Sirt-1 and p300, known histone acetyltransferases and 
histone deacetylases, respectively, were measured in order to understand the mechanisms 
underlying nicotine-induced epigenetic modifications (141, 145). While MNE-PL does 
not influence Sirt-1 or p300 mRNA expression in PND180 male offspring, I was only 
able to measure the indirect action of these enzymes. In future studies, I would like to 
employ a similar ChIP study to investigate changes in the in vivo binding of Sirt1 or p300 
to the FAS promoter directly. 
4.7 Early folic acid intervention in the prevention of permanent nicotine-induced 
disease outcomes in rat offspring 
 Since the development of the liver continues during early postnatal life, it is 
plausible that intervention during perinatal life could help reverse or prevent nicotine-
induced hypertriglyceridemia in adulthood (244). For example, short-term injections of 
Exendin-4 in neonatal life have been found to prevent oxidative stress, impaired 
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hepatic glucose production and hepatic insulin resistance normally exhibited in 
intrauterine growth restricted (IUGR) rat offspring (245).  
 Interestingly, folic acid supplementation has been demonstrated to reduce long-
term hypertriglycidemia in IUGR piglets via increased methylation of the promoter of 
LXR-target genes (246). Folate, and its synthetic form, folic acid, act as essential 
cofactors for biochemical reactions, namely the formation of S-adenosylmethionine, the 
main methyl donor for methylation (247).  A clinical study has demonstrated that 
differences in DNA methylation patterns can be detected in children exposed to smoke in 
utero (248).  Futhermore, folic acid has been shown to alleviate ER stress (249, 250). 
Taken together, it is conceivable that additional supplementation of folic acid may 
prevent adult onset hypertriglyceridemia in offspring exposed to nicotine through the 
prevention of aberrant epigenetic modulation and/or reduction of ER stress.  
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Future animal studies will investigate whether dietary folate supplementation can prevent 
or reduce nicotine-induced hypertriglyceridemia. I will administer nicotine alone, and in 
combination with folic acid to pregnant rats at clinically relevant doses to female rats 
during pregnancy and lactation (Fig. 4.7). I will evaluate whether folic acid 
supplementation prevents hypertriglyceridemia and/or activation of LXRα target genes in 
adult rat offspring. I will also assess whether folic acid supplementation reduces ER 
stress in liver of PND180 offspring.  
 
 
Fig. 4.7 Schematic overview of animal model of MNE-PL and folic acid 
intervention  
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